Emerging treatments in type 2 diabetes: Focus on canagliflozin

Therapeutics and Clinical Risk Management

Volumn 10, Issue 1, 2014, Pages 683-689

  Rosiak, Marek ^a,b   Grzeszczak, Susanna ^b   Kosior, Dariusz A ^b,c   Postuła, Marek ^a,b  

^a Department of Cardiology and Hypertension Central Clinical Hospital Ministry of the Interior ^*  (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

Author keywords

Blood pressure; Dapagliflozin; Hyperglycemia; Hypertension; Insulin resistance; Obesity; SGLT2 inhibitor; Weight loss

Indexed keywords

CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIMEPIRIDE; INSULIN; METFORMIN; PIOGLITAZONE; PLACEBO; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR;

ADJUVANT THERAPY; ANTIDIABETIC ACTIVITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; FUNGAL GENITAL INFECTION; HEADACHE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); POLLAKISURIA; POSITIONAL DIZZINESS; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; URINARY TRACT INFECTION;

EID: 84921496748     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S39145     Document Type: Review

References (28)

1. Danaei G, Finucane MM, Lu Y, et al; Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose). National, regional, and global trends in fasting plasma glucose and diabetes prevalence since1980: systematic analysis of health examination surveys and epidemiological studies with370 countryyears and2.7 million participants. Lancet.2011;378(9785): 31-40.
2. Bailey CJ. Renal glucose reabsorption inhibitors to treat diabetes. Trends Pharmacol Sci.2011;32(2):63-71.
3. Elkinson S, Scott L. Canagliflozin: first global approval. Drugs. 2013;73(9):979-988.
4. Triplitt CL. Understanding the kidneys' role in blood glucose regulation. Am J Manag Care.2012;18(Suppl1):S11-S16.
5. INVOKANA™ [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.;2013.
6. Committee for Medicinal Products for Human Use of the European Medicines Agency. EMA/374133/2013. Assessment report on the use of canagliflozin. London, UK: European Medicines Agency; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/ document_library/EPAR_-_Public_assessment_report/human/002649/ WC500156457.pdf. Accessed April2,2014.
7. Turk E, Martin MG, Wright EM. Structure of the human Na+/ glucose cotransporter gene SGLT1. J Biol Chem.1994;269(21): 15204-15209.
8. Kanai Y, Lee WS, You G, Brown D, Hediger MA. The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reasbsorptive mechanism for D-glucose. J Clin Invest. 1994;93(1):397-404.
9. Devineni D, Morrow L, Hompesch M, et al. Canagliflozin improves glycaemic control over28 days in subjects with type2diabetes not optimally controlled on insulin. Diabetes Obes Metab.2012;14(6): 539-545.
10. Sha S, Devineni D, Ghosh A, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab.2011;13(7): 669-672.
11. Janssen Pharmaceuticals Inc. Invokana™ (canagliflozin) tablets for oral use: US prescribing information. Titusville, NJ: Janssen Pharmaceuticals, Inc.;2013. Available from: http://www.janssenmd.com/pdf/invokana/ PI-INVOKANA.pdf. Accessed September1,2013.
12. Yale J, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type2diabetes and chronic kidney disease. Diabetes Obes Metab.2013;15(5):463-473.
13. Cefalu WT, Leiter LA, Yoon KH, et al. Eff icacy and safety of canagliflozin versus glimepiride in patients with type2 diabetes inadequately controlled with metformin (CANTATA-SU):52 week results from a randomised, double-blind, phase3non-inferiority trial. Lancet.2013;382(9896):941-950.
14. Nyirjesy P, Zhao Y, Ways K, Usiskin K. Evaluation of vulvovaginal symptoms and Candida colonization in women with type2diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2inhibitor. Curr Med Res Opin.2012;28(7):1173-1178.
15. Nisly S, Kolanczyk D, Walton A. Canagliflozin, a new sodium-glucose cotransporter2inhibitor, in treatment of diabetes. Am J Health Syst Pharm.2013;70(4):311-319.
16. Stenlöf K, Cefalu WT, Kim KA, et al. Eff icacy and safety of canagliflozin monotherapy in subjects with type2diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372-382.
17. Stenlöf K, Cefalu WT, Kim KA, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type2diabetes inadequately controlled with diet and exercise: findings from the52-week CANTATA-M study. Curr Med Res Opin.2013;15(4):372-382.
18. Janssen Research and Development, LLC. The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis-Metformin and Pioglitazone). Available from: http://clinicaltrials.gov/ct2/show/NCT01106690. NLM identifier: NCT01106690. Accessed September20,2013.
19. Janssen Research and Development, LLC [homepage on the Internet]. First Results from Phase3 CANVAS Trial Show Canagliflozin as Add-on Therapy to Insulin Lowered Blood Sugar Levels in Patients With Type2 Diabetes at an Elevated Risk for Cardiovascular Disease [October2,2012]. Titusville, NJ: Janssen Pharmaceuticals, Inc. Available from: http://www.investor.jnj.com/releasedetail. cfm?releaseid=710584. Accessed October23,2013.
20. Janssen Research and Development, LLC. A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type2Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise. Available from: http://clinicaltrials.gov/ct2/show/NCT01809327. NLM identifier: NCT01809327. Accessed September20,2013.
21. Janssen Scientific Affairs, LLC. Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type2Diabetes Mellitus on StableDoses of Anti-hyperglycemic and Anti-hypertensive Agents. Available from: http://clinicaltrials.gov/ ct2/show/NCT01939496. NLM identifier: NCT01939496. Accessed September20,2013.
22. Janssen-Cilag International NV. A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01877889. NLM identifier: NCT01877889. Accessed September20,2013.
23. Janssen Scientific Affairs, LLC. Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type2Diabetes Mellitus on StableDoses of Anti-hyperglycemic and Anti-hypertensive Agents. Available from: http://clinicaltrials.gov/ ct2/show/NCT01939496. NLM identifier: NCT01939496. Accessed September20,2013.
24. Taylor S, Harris K. The clinical efficacy and safety of sodium glucose cotransporter-2 inhibitors in adults with type2 diabetes mellitus. Pharmacotherapy.2013;33(9):984-999.
25. International Diabetes Federation. Global Guideline for Managing Older People with Type2Diabetes. Brussels, Belgium: International Diabetes Federation;2013. Available from: http://www.idf.org/sites/default/files/ IDF-Guideline-for-older-people-T2D.pdf. Accessed April2,2014.
26. National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type2 diabetes. Manchester, UK: National Institute for Health and Care Excellence;2013. Available from: http://www.nice.org.uk/nicemedia/live/14193/64270/64270.pdf. Accessed April2,2014.
27. Inagaki N, Kondo K, Yoshinari T, Maruyama N, Susuta Y, Kuki H. Efficacy and safety of canagliflozin in Japanese patients with type2 diabetes: a randomized, double-blind, placebo-controlled,12 week study. Diabetes Obes Metab.2013;15(12):1136-1145.
28. Rosenstock J, Aggarwal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter2inhibitor, as add-on to metformin in subjects with type2diabetes. Diabetes Care.2012;35(6): 1232-1238.